Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis

A case-control study

Adriana Ammassari, Angela Linzalone, Rita Murri, Giuseppe Marasca, Giulia Morace, Andrea Antinori

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In order to verify whether fluconazole has a prophylactive effect against the occurrence of cryptococcosis in HIV-infected patients and to identify other factors capable of increasing or reducing the risk of this infection, we arranged a case-control study of 17 patients with cryptococcal infection. 34 controls were selected, matched by presence of an AIDS-defining event, CD4 cell count, and date of T-cell phenotyping. No significant difference in exposure to fluconazole, in total days of treatment, or in total dose administered was observed between cases and controls. However, control patients took a significantly higher average daily dosage of fluconazole and a linear tendency in risk reduction (p = 0.04) in relation to increasing dosage was observed. Antiretroviral therapy and an average daily fluconazole dose exceeding 150 mg both each reduced the risk of a cryptococcal infection.

Original languageEnglish
Pages (from-to)235-237
Number of pages3
JournalScandinavian Journal of Infectious Diseases
Volume27
Issue number3
DOIs
Publication statusPublished - 1995

Fingerprint

Cryptococcosis
Fluconazole
Case-Control Studies
Acquired Immunodeficiency Syndrome
Infection
Risk Reduction Behavior
CD4 Lymphocyte Count
HIV
T-Lymphocytes
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Immunology

Cite this

Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis : A case-control study. / Ammassari, Adriana; Linzalone, Angela; Murri, Rita; Marasca, Giuseppe; Morace, Giulia; Antinori, Andrea.

In: Scandinavian Journal of Infectious Diseases, Vol. 27, No. 3, 1995, p. 235-237.

Research output: Contribution to journalArticle

Ammassari, Adriana ; Linzalone, Angela ; Murri, Rita ; Marasca, Giuseppe ; Morace, Giulia ; Antinori, Andrea. / Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis : A case-control study. In: Scandinavian Journal of Infectious Diseases. 1995 ; Vol. 27, No. 3. pp. 235-237.
@article{3372ef64ec8a41aba5d16300f895a099,
title = "Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: A case-control study",
abstract = "In order to verify whether fluconazole has a prophylactive effect against the occurrence of cryptococcosis in HIV-infected patients and to identify other factors capable of increasing or reducing the risk of this infection, we arranged a case-control study of 17 patients with cryptococcal infection. 34 controls were selected, matched by presence of an AIDS-defining event, CD4 cell count, and date of T-cell phenotyping. No significant difference in exposure to fluconazole, in total days of treatment, or in total dose administered was observed between cases and controls. However, control patients took a significantly higher average daily dosage of fluconazole and a linear tendency in risk reduction (p = 0.04) in relation to increasing dosage was observed. Antiretroviral therapy and an average daily fluconazole dose exceeding 150 mg both each reduced the risk of a cryptococcal infection.",
author = "Adriana Ammassari and Angela Linzalone and Rita Murri and Giuseppe Marasca and Giulia Morace and Andrea Antinori",
year = "1995",
doi = "10.3109/00365549509019015",
language = "English",
volume = "27",
pages = "235--237",
journal = "Scandinavian Journal of Infectious Diseases",
issn = "0036-5548",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis

T2 - A case-control study

AU - Ammassari, Adriana

AU - Linzalone, Angela

AU - Murri, Rita

AU - Marasca, Giuseppe

AU - Morace, Giulia

AU - Antinori, Andrea

PY - 1995

Y1 - 1995

N2 - In order to verify whether fluconazole has a prophylactive effect against the occurrence of cryptococcosis in HIV-infected patients and to identify other factors capable of increasing or reducing the risk of this infection, we arranged a case-control study of 17 patients with cryptococcal infection. 34 controls were selected, matched by presence of an AIDS-defining event, CD4 cell count, and date of T-cell phenotyping. No significant difference in exposure to fluconazole, in total days of treatment, or in total dose administered was observed between cases and controls. However, control patients took a significantly higher average daily dosage of fluconazole and a linear tendency in risk reduction (p = 0.04) in relation to increasing dosage was observed. Antiretroviral therapy and an average daily fluconazole dose exceeding 150 mg both each reduced the risk of a cryptococcal infection.

AB - In order to verify whether fluconazole has a prophylactive effect against the occurrence of cryptococcosis in HIV-infected patients and to identify other factors capable of increasing or reducing the risk of this infection, we arranged a case-control study of 17 patients with cryptococcal infection. 34 controls were selected, matched by presence of an AIDS-defining event, CD4 cell count, and date of T-cell phenotyping. No significant difference in exposure to fluconazole, in total days of treatment, or in total dose administered was observed between cases and controls. However, control patients took a significantly higher average daily dosage of fluconazole and a linear tendency in risk reduction (p = 0.04) in relation to increasing dosage was observed. Antiretroviral therapy and an average daily fluconazole dose exceeding 150 mg both each reduced the risk of a cryptococcal infection.

UR - http://www.scopus.com/inward/record.url?scp=0029085144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029085144&partnerID=8YFLogxK

U2 - 10.3109/00365549509019015

DO - 10.3109/00365549509019015

M3 - Article

VL - 27

SP - 235

EP - 237

JO - Scandinavian Journal of Infectious Diseases

JF - Scandinavian Journal of Infectious Diseases

SN - 0036-5548

IS - 3

ER -